Eli Lilly and Pfizer to collaborate on tanezumab programme for Osteoarthritis

Pfizer is planning to continue development of tanezumab (CP 690,550) for the treatment of Osteoarthritis, Chronic Low Back Pain and Cancer Pain, and has just entered into a collaboration agreement with Eli Lilly & Company to jointly develop and globally commericialize tanezumab, which provides that Pfizer and Lilly will equally share product development expenses as well as potential revenues and certain product-related costs. The tanezumab program currently is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Pfizer anticipates submitting that data in the first half of 2014.